Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities

doi:10.4254/wjh.v13.i11.1568

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5416)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

453

WORD

169

HTML

3169

Figures (1-5)

223

Tables (1-2)

219

Sum=4233

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

401

Download

782

Sum=1183

Nov 27, 2021 (publication date) through Jul 29, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Nov 27, 2021; 13(11): 1568-1583
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1568

Table 2 List of Food and Drug Administration approved/under trial epi-drugs

Drugs	Classification	Approved year	Indicated disease	Reference/ clinical trial number
Azacytidine	DNMT inhibitor	2004	MDS	NCT01186939
		2009	AML	NCT00887068
Decitabine	DNMT inhibitor	2006	MDS	NCT01751867
		2011	AML	NCT00260832
Vorinostat	HDAC inhibitor	2006	CTCL	NCT00773747
Romidepsin	HDAC inhibitor	2009	TCL	NCT02296398
Belinostat	HDAC inhibitor	2015	PTCL	NCT01839097
Panobinostat	HDAC inhibitor	2015	MM	NCT01023308
		2016	CML	NCT00451035
		2017	TCL	NCT00490776

MDS: Myelodysplastic syndrome; AML: Acute myeloid leukemia; CTCL: Cutaneous T cell lymphoma; TCL: T-cell lymphoma; PTCL: Peripheral T cell lymphoma; MM: Multiple myeloma; CML: Chronic myeloid leukemia; HDAC: Histone deacetylase; DNMT: DNA methyltransferase.

Citation: Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583
URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1568.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1568